Anti-tumor effect of lentivirus-mediated gene transfer of alphastatin on human glioma.
Alphastatin, an endogenous angiogenesis inhibitor, has recently been used as an anticancer agent in several tumor models. This study was to investigate whether local sustained long-term expression of alphastatin could serve to diminish tumor growth of a human xenograft glioma model. We found that the recombinant alphastatin lentiviruses were able to stably infect HUVECs, and infected HUVECs could sustainably secrete alphastatin, which exhibited potent inhibitory effects on HUVECs migration, differentiation but not proliferation induced by vascular endothelial growth factor (VEGF) or basic fibroblast growth factor(bFGF). And the expression of secreted protein alphastatin markedly decreased tumor vascularization and inhibited tumor growth. Additionally, alphastatin inhibited VEGF- or bFGF-induced initial stage of angiogenesis by reducing JNk and ERK phosphorylation in vitro. Taken together, these data demonstrate that secreted protein alphastatin inhibits VEGF- or bFGF-induced angiogenesis by suppressing JNK and ERK kinases activation pathways in HUVECs, and markedly inhibits tumor angiogenesis in vivo. Consequently lentivirus-mediated gene transfer might represent an effective strategy for expression of alphastatin to achieve inhibition of human malignant glioma proliferation and tumor progression.
Department of Neurosurgery, First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, China. gsw1962@126.com
Shi-Wen
SW
Guo
Hong-Min
HM
Che
Wen-Zhi
WZ
Li
D000818:Animals; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D042783:Endothelial Cells; D005340:Fibrinogen / Q000235:genetics*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D005910:Glioma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007150:Immunohistochemistry; D016086:Lentivirus / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000628:therapy*; D023041:Xenograft Model Antitumor Assays
C514422:alphastatin; D005340:Fibrinogen
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11382-8
8876144
Cancer Cell. 2007 Jan;11(1):69-82
17222791
Br J Cancer. 1999 Dec;81(8):1318-27
10604728
J Clin Invest. 1973 Nov;52(11):2745-56
4355998
Blood. 2004 Jan 15;103(2):601-6
14512300
Blood. 2006 Apr 15;107(8):3027-33
16373660
J Biol Chem. 2000 Apr 7;275(14):10661-72
10744763
Cancer Metastasis Rev. 2000;19(1-2):181-90
11191058
J Neurosci Methods. 2009 Dec 15;185(1):1-14
19699233
Cancer Invest. 2008 Feb;26(1):28-34
18181042
Cardiovasc Res. 2001 Feb 16;49(3):507-21
11166264
Oncogene. 2004 Jan 15;23(2):434-45
14724572
J Neurosci. 2003 Mar 15;23(6):1992-6
12657655
Cell. 1983 Feb;32(2):639-46
6297804
Microbiol Mol Biol Rev. 2004 Jun;68(2):207-33
15187182
World J Gastroenterol. 2006 Jul 14;12(26):4130-6
16830360
EMBO J. 2003 Jul 15;22(14):3479-85
12853463
Nat Neurosci. 2000 Apr;3(4):350-7
10725924
Cell. 1996 Aug 9;86(3):353-64
8756718
Glia. 1995 Nov;15(3):339-47
8586468
Cancer Gene Ther. 2001 Nov;8(11):879-89
11773978
Oncogene. 2004 Jan 8;23(1):192-200
14712224
World J Gastroenterol. 2009 Dec 14;15(46):5813-20
19998502
Cancer Cell. 2002 Mar;1(2):125-8
12086870
Cancer Invest. 2010 Jun;28(5):465-71
19968500
Cancer. 1992 Dec 1;70(11):2673-80
1423198
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9064-6
9689032
Science. 1996 Apr 12;272(5259):263-7
8602510
Cancer Cells. 1990 Jun;2(6):179-85
1696827
Endocr Rev. 2004 Aug;25(4):581-611
15294883
Exp Cell Res. 1999 Jul 10;250(1):168-73
10388530
J Histochem Cytochem. 1994 Aug;42(8):1127-34
8027531
Proteomics. 2006 Jun;6(12):3636-48
16705751
Nat Biotechnol. 1997 Sep;15(9):871-5
9306402
Oncogene. 2000 Apr 20;19(17):2138-46
10815805
Microbiology (Reading). 2000 Jan;146 ( Pt 1):77-88
10658654
Cancer. 1996 Jan 15;77(2):362-72
8625246
J Thromb Haemost. 2007 Apr;5(4):846-54
17408413
Antisense Nucleic Acid Drug Dev. 1999 Oct;9(5):481-6
10555156
J Natl Cancer Inst. 1998 Feb 18;90(4):273-86
9486813
J Virol. 1998 Dec;72(12):9873-80
9811723